(Elhuyar Fundazioa) International research involving the University Hospital of the University of Navarra, together with other hospitals in Spain, has shown that Sorafenib, an orally administered pharmaceutical medicine, results in patients with primary hepatocarcinomas to live 40 percent more on average compared to those not taking the drug.
Post new comment